Abstract 215P
Background
Introduction: About 2-3% of all cancers are renal cell carcinoma (RCC). Nephrectomy is the main treatment. The decision among radical and partial nephrectomy often relies on the tumor size diagnosed by CT scan. It is thus justified to investigate the variation between the radiologic and pathologic size of the tumor and its implications on the management of renal cell carcinoma. Aim: To assess the variation between the radiologic tumor size (RTS) of localized renal cell cancer as measured by Computed tomography (CT) preoperatively and the pathologic tumor size (PTS) as determined from surgical specimen postoperatively.
Methods
The records of 240 patients who underwent nephrectomy due to RCC were taken from the Urology Department of Trivandrum Medical College, Kerala, India. The difference of means for the tumor size on Computed Tomography (CT) scan/ the radiologic tumor size (RTS) and pathologic tumor size (PTS) was calculated using paired T test; the difference was also categorised in terms of sex, type of RCC, type of nephrectomy and T staging. A p value of < 0.05 was considered statistically significant.
Results
The mean age of cases included was 54.82 years (22-78 years) (SD 10.991). The mean RTS was larger than PTS (5.22 ± 2.15 vs. 4.98 ± 2.04 cm, p = <0.001) with a discrepancy of 0.24 cm. The difference among means was found significant for both males and females; significant among clear cell RCC and non - clear cell RCC; and significant for radical neohrectomy but not for partial nephrectomy. Overall 41 of the 240 tumors were down-staged while another 5 up-staged.
Table: 215P Characteristics of the 240 patients with localized renal cell carcinoma
Number of patients | 240 | |
Average age (years) | 54.82 (SD 10.991) | |
Gender- | ||
Male | 159 (66.2%) | |
Female | 81 (33.8%) | |
Histopathologic type- | ||
Clear Cell Carcinoma | 198 (82.5%) | |
Total-Non Clear Cell Carcinoma | 42 (17.5%) | |
Papillary | 22 (9.2%) | |
Chromophobe | 7 (2.9%) | |
PNET | 3 (1.2%) | |
Sarcomatoid | 5 (2.1%) | |
Unclassified | 5 (2.1%) | |
Average tumor size- | ||
RTS | 5.22 (SD 2.15) | |
PTS | 4.98 (SD 2.04) | |
Average difference between RTS and PTS- | 0.24 (SD 0.37) | |
Fuhrman grade | ||
I | 10 (4.2%) | |
II | 177 (73.8%) | |
III | 45 (18.8%) | |
IV | 8 (3.3%) | |
T stage- | Radiologic | Pathologic |
T1a | 100 (41.7%) | 121 (50.4%) |
T1b | 102 (42.5%) | 95 (39.6%) |
T2a | 30 (12.5%) | 17 (7.1%) |
T2b | 8 (3.3%) | 7 (2.9%) |
Stage change- | ||
Down-staged | 41 (17.1%) | |
Up-staged | 5 (2.1%) | |
Total | 46 (19.2%) |
Conclusions
There can be a discrepancy between radiologic size and pathologic tumor size in renal cell cancer which bears repercussions for its management. Message: Mangement of renal cell carcinoma should be carefully selected based on the tumor size diagnosed by CT scan.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
9P - XRCC1 Arg194Trp, Palb2 T1100T (3300T>G), HMMR V353A, TNF aG308A polymorphisms as diagnostic and prognostic markers of breast cancer in the Kyrgyz ethnic group
Presenter: Aigul Semetei kyzy
Session: Poster display session
Resources:
Abstract
232P - Early Results from the Phase I Study of SY-1365, a Potent and Selective CDK7 inhibitor, in Patients with Ovarian Cancer and Advanced Solid Tumors
Presenter: Debra Richardson
Session: Poster display session
Resources:
Abstract
382P - Drug metabolizing enzymes pharmacogenomic: Biomarkers for improved chemotherapy in head and neck cancer squamous cell carcinoma
Presenter: Sunishtha Bhatia
Session: Poster display session
Resources:
Abstract
401P - Women in oncology: Alarming figures from India
Presenter: Sharada Mailankody
Session: Poster display session
Resources:
Abstract
416P - Multidisciplinary management of sarcomas of the head and neck: An institutional experience
Presenter: Kavitha Jain
Session: Poster display session
Resources:
Abstract
523P - Co-morbilities and survival of patients initially diagnosed with extensive-stage small cell lung cancer: Impact of hypertension, diabetes and chronic hepatitis B viral infection
Presenter: Weigang Xiu
Session: Poster display session
Resources:
Abstract
529P - Osimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II study
Presenter: Roni Gillis
Session: Poster display session
Resources:
Abstract